Peter T. Symanowicz
Pfizer (United States)(US)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography
Most-Cited Works
- → Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition(2016)189 cited
- → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
- → Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases(2018)163 cited
- → Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design(2017)139 cited
- → JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production(2012)134 cited
- → The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial(2021)89 cited
- → Selective functional inhibition of JAK‐3 is sufficient for efficacy in collagen‐induced arthritis in mice(2010)74 cited
- → Network pharmacology of JAK inhibitors(2016)66 cited
- → Immediate sensory nerve-mediated respiratory responses to irritants in healthy and allergic airway-diseased mice(2003)66 cited
- → Lack of role for the vanilloid receptor in response to several inspired irritant air pollutants in the C57Bl/6J mouse(2004)46 cited